Pricing methods in outcome-based contracting: δ3: reference-based pricing-Reference-Cited by-同舟云学术

Pricing methods in outcome-based contracting: δ3: reference-based pricing

Published:2020-09-08 Issue:11 Volume:23 Page:1230-1236
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Alkhatib Nimer S.¹²^ORCID,Erstad Brian¹³,Ramos Kenneth⁴,McBride Ali³⁵⁶,Bhattacharjee Sandipan¹³,Slack Marion¹³,Abraham Ivo¹³⁶⁷⁸^ORCID

Affiliation:

1. Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, University of Arizona, Tucson, AZ, USA

2. College of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan

3. Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ, USA

4. Institute of BioSciences and Technology, Texas A&M University, Houston, TX, USA

5. Banner University Medical Center, Tucson, AZ, USA

6. University of Arizona Cancer Center, University of Arizona, Tucson, AZ, USA

7. Department of Family and Community Medicine, College of Medicine, University of Arizona, Tucson, AZ, USA

8. Matrix45, Tucson, AZ, USA

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2020.1815027

Reference17 articles.

1. Pricing methods in outcome-based contracting: δ1: cost effectiveness analysis and cost-utility analysis-based pricing

2. Pricing methods in outcome-based contracting: δ2: willingness-to-pay-based pricing

3. World Health Organization. WHO guideline on country pharmaceutical pricing policies. [cited Dec 2019]. Available from: https://apps.who.int/medicinedocs/documents/s21016en/s21016en.pdf

4. Higher US Branded Drug Prices And Spending Compared To Other Countries May Stem Partly From Quick Uptake Of New Drugs

5. Sarnak DO, Squires D, Bishop S. Paying for prescription drugs around the world: why is the U.S. an outlier. [cited December 2019]. Available from: https://www.commonwealthfund.org/publications/issue-briefs/2017/oct/paying-prescription-drugs-around-world-why-us-outlier

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The status and preparation for the next decade of biosimilars in the Middle Eastern and North African region;Expert Opinion on Biological Therapy;2023-07-26

2. Cost-efficiency analysis and expanded treatment access modeling of conversion to rituximab biosimilars from reference rituximab in Jordan;Journal of Medical Economics;2023-06-30

3. Value elements and methods of value-based pricing for drugs in Japan: a systematic review;Expert Review of Pharmacoeconomics & Outcomes Research;2023-06-20

4. The six Delta platform for outcome-based contracting for pharmaceuticals;Journal of Medical Economics;2020-09-29

5. Pricing methods in outcome-based contracting: δ6: adherence-based pricing;Journal of Medical Economics;2020-09-10